Management ChangeAug 10, 2026, 09:10 AM
Ernexa Appoints David Polinsky to Board of Directors
AI Summary
Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors. Mr. Polinsky, a seasoned biotechnology founder and public company CFO, brings over 25 years of experience in oncology, capital markets, M&A, and corporate governance. This appointment strengthens the company's leadership team as it prepares for the Investigational New Drug (IND) submission for its lead program, ERNA-101, in Q3 2026, and the initiation of its first Phase 1 clinical study in Q4 2026.
Key Highlights
- Ernexa Therapeutics appointed David Polinsky to its Board of Directors.
- Mr. Polinsky brings over 25 years of leadership in oncology, capital markets, M&A, and corporate governance.
- He currently serves as Chief Financial Officer of Rafael Holdings, Inc.
- The appointment strengthens the leadership team for upcoming clinical milestones.
- ERNA-101 Investigational New Drug (IND) application planned for Q3 2026.
- ERNA-101 Phase 1 clinical study initiation planned for Q4 2026.
- Mr. Polinsky co-founded Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals).
Price Impact
More from ERNA